Results 41 to 50 of about 15,630 (215)

Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn's Disease: A Prospective Study [PDF]

, 2021
No data are available regarding the safety and effectiveness of the biosimilar-to-biosimilar switch of adalimumab in any disease, and in particular in Crohn’s disease (CD).
Vernero, Marta, Caviglia, Gian Paolo, Elisabetta Bugianesi, Rosso, Chiara, Armandi, Angelo, Davide Giuseppe Ribaldone, Elisa Tribocco, Astegiano, Marco, Saracco, Giorgio Maria, Bugianesi, Elisabetta, Marta Vernero, Gian Paolo Caviglia, Ribaldone, Davide Giuseppe, Angelo Armandi, Chiara Rosso, Marco Astegiano, Giorgio Maria Saracco   +16 more
core   +1 more source

Dose equivalency and efficacy of biosimilar erythropoietin stimulating agents: Data from real clinical practice

Pharmacology Research & Perspectives, 2020
Recently, biosimilar erythropoietin stimulating agents become available in Kazakhstan. Important properties of the biosimilar such as dose equivalency to the original medicine (originator) and the ability to maintain hemoglobin target levels remain ...
Abduzhappar Gaipov, Alpamys Issanov, Zhanar Mursalova, Nazia Tulegenova, Zoya Kakim, Mukhit Baizakov, Saltanat Tuganbekova, Mohamad Aljofan   +7 more
doaj   +1 more source

Changing trends in the use of anti-vascular endothelial growth factor (anti-VEGF) biosimilars: Insights from the Vitreoretinal Society of India Biosimilars of Anti-VEGF Survey

Indian Journal of Ophthalmology, 2021
Purpose: The aim of this study was to present the outcomes of the 2018 and 2020 Vitreo-retinal Society of India (VRSI) biosimilars of anti-vascular endothelial growth factor (VEGF) (VIBE) surveys.
Jay U Sheth, Michael W Stewart, Manoj Khatri, Shashank R Gupta, Shobhit Chawla, Anand Rajendran, Raja Narayanan   +6 more
doaj   +1 more source

Biosimilars – terms of use [PDF]

Current Medical Research and Opinion, 2015
The impending expiry of the patent on a number of leading biologic drugs has led to a surge in the development of 'biosimilar' or 'follow-on' products. However, in contrast to generic small-molecule medicines, biosimilars are not identical to their reference products.
Declerck, Paul, Mellstedt, Håkan, Danese, Silvio   +2 more
openaire   +4 more sources

Imbalanced machine learning classification models for removal biosimilar drugs and increased activity in patients with rheumatic diseases.

PLoS ONE, 2023
ObjectivePredict long-term disease worsening and the removal of biosimilar medication in patients with rheumatic diseases.MethodologyObservational, retrospective descriptive study.
David Castro Corredor, Luis Ángel Calvo Pascual   +1 more
doaj   +1 more source

Mechanical Flexibility Enables DNA Origami to Overcome Steric Confinement in Mucus

Advanced Science, EarlyView.
Mechanical flexibility is introduced as a design parameter to enhance nanocarrier transport in mucus. Using DNA origami, flexibility is decoupled from size, shap and surface chemistry, revealing improved passage through confined hydrogel networks. While surface passivation reduces aggregation, flexibility further boosts transport, offering a general ...
Matteo Tollemeto, Emily Tsang, Marie Karen Tracy Hong Lin, Luca Mannino, Kurt V. Gothelf, Anja Boisen   +5 more
wiley   +1 more source

Population Pharmacokinetic Modeling of TV-46000, a Risperidone Long-Acting Subcutaneous Antipsychotic for the Treatment of Patients with Schizophrenia

Neurology and Therapy
Introduction TV-46000 is a long-acting subcutaneous antipsychotic (LASCA) agent that combines risperidone and an innovative, copolymer-based drug delivery technology in a suspension suitable for subcutaneous administration from a prefilled syringe.
Itay Perlstein, Avia Merenlender Wagner, Anna Elgart, Anthe S. Zandvliet, Farina Hellmann, YuWei Lin, Eline van Maanen, Nele Plock, Floris Fauchet, Rajendra Singh   +9 more
doaj   +1 more source

Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi Panel

Frontiers in Pharmacology, 2017
Introduction: Introducing biosimilar infliximab for the treatment in rheumatology (rheumatoid arthritis and ankylosing spondylitis) and inflammatory bowel disease (Crohn's disease and ulcerative colitis) may reduce treatment costs associated with ...
Tim A. Kanters, Jelena Stevanovic, Jelena Stevanovic, Isabelle Huys, Arnold G. Vulto, Steven Simoens   +5 more
doaj   +1 more source

Biosimilars in rheumatology

Pharmacological Research, 2019
Biotechnologicals are an invaluable resource in the treatment of patients with inflammatory rheumatic diseases (IRD) non-responsive or intolerant to conventional therapies. However, they are the main driver for increase in direct costs and represent a significant economic burden to healthcare systems worldwide.
Araújo, Filipe C., Goncalves, Joao, Fonseca, João Eurico   +2 more
openaire   +3 more sources

Biosimilars in oncology

ESMO Open, 2018
Biosimilars will soon become broadly available in the oncology field, raising important questions from both patients and healthcare providers. These questions need to be clarified upfront, in order to increase confidence in using these therapies. In this podcast, Teresa Amaral (Young Oncologist Committee member) talks to Josep Tabernero (ESMO President
openaire   +3 more sources